Clinical Trials
34
Active:5
Completed:29
Trial Phases
3 Phases
Phase 1:26
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (30 trials with phase data)• Click on a phase to view related trials
Phase 1
26 (86.7%)Phase 2
2 (6.7%)phase_1_2
1 (3.3%)Phase 3
1 (3.3%)A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog® Mix25Drug: Euglycemic clamp with Humalog® and Lantus®
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-10-12
- Lead Sponsor
- Adocia
- Target Recruit Count
- 27
- Registration Number
- NCT05373186
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial Comparing the Pharmacodynamics and Pharmacokinetics of BC Combo THDB0207 and Lantus® and Humalog® in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog®Drug: Euglycemic clamp with Lantus®
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Adocia
- Target Recruit Count
- 30
- Registration Number
- NCT05373199
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial Investigating the Dose Linearity and Safety of BC Combo THDB0207 in Subjects With Type 2 Diabetes
Phase 1
Completed
- Conditions
- Type 2 Diabetes
- Interventions
- Drug: Euglycemic clamp with BC Combo THDB0207Drug: Euglycemic clamp with Humalog® Mix25
- First Posted Date
- 2022-05-13
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Adocia
- Target Recruit Count
- 40
- Registration Number
- NCT05373212
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial to Assess the Efficacy and Safety of M1 Pram P037 Prandial Insulin in Subjects With Type 1 Diabetes (T1DM)
Phase 2
Completed
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- Drug: M1 Pram P037
- First Posted Date
- 2021-03-25
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Adocia
- Target Recruit Count
- 80
- Registration Number
- NCT04816890
- Locations
- 🇩🇪
Profil Mainz GmbH & Co, Mainz, Germany
🇩🇪Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
A Trial to Compare BioChaperone Insulin Lispro Formulations With US Approved Humalog® and With EU Approved Humalog® in Patients With Type 1 Diabetes Mellitus
Phase 1
Completed
- Conditions
- Type 1 Diabetes
- Interventions
- Drug: Administration of BioChaperone insulin lispro reconstituted with Humalog® (IMP1)Drug: Administration of Ready-to-use BioChaperone insulin lispro (IMP2)Drug: Administration of US-approved Humalog® (IMP3)Drug: Administration of EU-approved Humalog® (IMP4)
- First Posted Date
- 2020-08-06
- Last Posted Date
- 2020-11-30
- Lead Sponsor
- Adocia
- Target Recruit Count
- 32
- Registration Number
- NCT04501107
- Locations
- 🇩🇪
Profil GmbH, Mainz, Germany
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
News
Monthly Semaglutide Injection Shows Promise in Early Trials
A novel hydrogel formulation of semaglutide allows for a slow, steady release of the drug over one month, potentially reducing the frequency of injections.